Last reviewed · How we verify
PrEP using Truvada
At a glance
| Generic name | PrEP using Truvada |
|---|---|
| Also known as | Combination of Tenofovir disoproxyl fumarate 300mg and Emtricitabine 200 mg |
| Sponsor | CHU de Quebec-Universite Laval |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pre-Exposure Prophylaxis for Transgender Women in the US and South America (PHASE2, PHASE3)
- Pre-Exposure Prophylaxis in the Emergency Department (NA)
- Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France. (PHASE3)
- SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder (PHASE3)
- WePrEP: Developing a PrEP Shared Decision-making Tool for Transgender Women (NA)
- PrEPsmart 2-1-1 Pilot (PHASE2)
- Next Generation Ingestible Sensors for Medication Adherence Measurement (PHASE3)
- Virtual PrEP: Rendering PrEP Delivery More Efficient (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PrEP using Truvada CI brief — competitive landscape report
- PrEP using Truvada updates RSS · CI watch RSS
- CHU de Quebec-Universite Laval portfolio CI